• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Adjuvant Clonidine for Mania
Research Update

Adjuvant Clonidine for Mania

March 8, 2023
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Michael Posternak, MD. Dr. Posternak has no financial relationships with companies related to this material.

REVIEW OF: Ahmadpanah M et al, J Psych Research 2022;146:163–171

STUDY TYPE: Randomized controlled trial

Long ago in the 1980s, clonidine showed promise in an open-label and a small controlled trial of bipolar mania, but those findings were never followed up until now. This antihypertensive has alpha-agonist as well as serotonergic and dopaminergic effects. It is well tolerated and has potential benefits in symptoms that are relevant to mania, including insomnia, anxiety, and irritability. Clonidine is FDA approved in ADHD, and this study tested whether it would also improve cognition during active mania.

Researchers in Iran randomized 70 inpatients with acute mania to receive either adjuvant clonidine or placebo in addition to lithium (dosage range 900–1200 mg/day) over the course of 24 days. Clonidine was started at 0.2 mg/day and titrated toward a maximum of 0.6 mg/day (given as two divided doses in the evening). The primary outcome was improvement in mania as measured by the Young Mania Rating Scale (YMRS). Secondary outcomes were sleep as measured by the Pittsburgh Sleep Quality Index (PSQI) and cognition as measured by the Mini-Mental State Examination (MMSE).

Compared to placebo, those on adjuvant clonidine achieved significantly lower endpoint YMRS scores on day 24 (9.8 vs 13.6) and slept better (PSQI = 4.5 vs 5.9), but no differences were found in cognition as measured by the MMSE. The corresponding effect sizes were large for mania (0.9) and medium for sleep (0.6). Adverse effects were not reported, but typical tolerability issues with clonidine include sedation and hypotension (in this study, the drug was held if the blood pressure dropped below 100/60 mmHg for two consecutive days).

The majority (84%) of patients were male, which may limit the generalizability of the findings. Also, the MMSE is a coarse instrument for measuring cognition, and it is possible that subtle differences in cognition were not elicited by this instrument.

CARLAT TAKE

Consider clonidine augmentation in mania when patients don’t respond to or cannot tolerate conventional option

General Psychiatry Research Update
KEYWORDS bipolar bipolar disorder cognition mania mood disorders
    Michael Posternak, MD.

    Psychological Benefits of Abstaining from Social Media

    More from this author
    www.thecarlatreport.com
    Issue Date: March 8, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Complementary Therapies, TCPR, March 2023
    Deep Rivers Run Quiet. An Update on Social Anxiety Disorder
    Herbal Therapies for Depression
    Four Controversial Diagnoses in Psychiatry: Are They Valid?
    Adjuvant Clonidine for Mania
    CME Post-Test, Complementary Therapies, TCPR, March 2023
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.